This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
GLOW with KPV added — the four-pathway recovery stack for researchers focused on gut inflammation, IBD models, or comprehensive gut + tissue healing. One vial, one injection.
KLOW is GLOW with KPV added. KPV (Lysine-Proline-Valine) is a tripeptide derived from alpha-melanocyte-stimulating hormone (α-MSH) with potent anti-inflammatory and gut-healing properties that complement and amplify the BPC-157 gut healing already present in the base formula.
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone — the anti-inflammatory signaling domain of α-MSH, without the pigmentation effects of the full molecule. It directly inhibits NF-κB, the master regulator of inflammatory gene expression. In gut models, KPV penetrates intestinal epithelial cells and reaches the nucleus — reducing inflammatory cytokine production at the source. Combined with BPC-157's gut-healing signaling, KLOW creates a two-vector anti-inflammatory and barrier repair approach that neither peptide achieves alone.
KPV + BPC-157 dual anti-inflammatory and barrier repair. KPV reduces NF-κB inflammatory signaling; BPC-157 stimulates gut epithelial repair and growth factor signaling. Together: the most comprehensive gut healing combination available.
KPV directly inhibits NF-κB nuclear translocation — the transcription factor controlling TNF-α, IL-6, IL-1β production. This is the primary mechanism behind KPV's documented effects in IBD and intestinal inflammation models.
GHK-Cu's collagen synthesis + BPC-157's tendon fibroblast activation + TB-500's cell migration work in complementary fashion to rebuild connective tissue from multiple angles simultaneously.
The BPC-157 + TB-500 recovery stack is intact inside KLOW — all the tendon, ligament, and tissue repair benefits, with KPV adding systemic anti-inflammatory support to reduce the inflammatory burden at injury sites.
BPC-157 activates VEGFR2; TB-500 drives cell migration-mediated angiogenesis. New blood vessel formation improves healing environment for gut lining and musculoskeletal tissue alike.
KPV (NF-κB inhibition) + GHK-Cu (collagen/gene reset) + BPC-157 (receptor signaling) + TB-500 (cell migration) — four distinct mechanisms, one reconstitution, one draw, one injection.
Same reconstitution and injection protocol as GLOW. Because KLOW is a four-analyte blend, the COA verifies each component separately — confirm identity and purity of all four before use.
| Parameter | Detail |
|---|---|
| Reconstitution | Add 2–5 mL bacteriostatic water gently to lyophilized powder |
| Frequency | Once daily or every other day |
| Route | Subcutaneous — abdomen, upper thigh |
| Cycle Length | 4 – 12 weeks depending on protocol goals |
| Storage (reconstituted) | Refrigerate; use within 30 days |
Choose GLOW for pure recovery, tissue repair, and skin regeneration. Choose KLOW when gut inflammation, IBD research, or combined gut + tissue healing is the primary focus. Both share the GHK-Cu + BPC-157 + TB-500 core.
KLOW is a pre-blended peptide combination sold for research purposes only. None of the components are FDA-approved drugs for the uses described. The information on this page is educational and does not constitute medical advice. Consult a qualified healthcare professional before any peptide protocol.
Pre-blended. Quad-analyte COA. Finnrick Analytics verified. Ships within 24 hours.
Get Started TodayMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.